How The Allure Of Abivax Kept Marc de Garidel From The Beach
Lays Out Ambitious Plans
Executive Summary
Abivax has had its ups and downs but newly appointed CEO Marc de Garidel tells Scrip he is confident that the French group is onto a winner with its ulcerative colitis drug, obefazimod.
You may also be interested in...
With Strong Anti-Inflammatory Candidate In Hand, Abivax Execs Carve A Path Forward
With a strong late-stage anti-inflammatory molecule in its pipeline, the challenge for Abivax is to garner the funds to take its obefazimod program forward. To that end, the company is continuing to do a major overhaul of personnel and is sharpening its corporate vision.
Morphic Shows Potential For An ‘Oral Entyvio’ With Phase IIa Data
MORF-057, addressing the same target as Takeda blockbuster Entyvio, shows efficacy and safety in ulcerative colitis. Various companies have sought an oral competitor to established biologics in UC.
How HALO Slip Proved Costly For CinCor In AstraZeneca Talks
Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a $26 bid won the day earlier this month.